Latest Breaking News On - Adriaan voors - Page 1 : comparemela.com

Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

In what might prove the swan song for ERAs in HF, SERENADE tried to exclude patients with fluid retention to no avail.

Experimental heart failure drug has little impact on exercise tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on their ability to exercise compared to a placebo, according to a study supported by the Duke Clinical Research Institute.

Investigational Drug for Heart Failure has Little Impact on Exercise Tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on t

Empagliflozin benefits adults hospitalised for acute heart failure

Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.